Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Common Equity (2021 - 2025)

Historic Common Equity for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $9.6 million.

  • InMed Pharmaceuticals' Common Equity rose 5508.75% to $9.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.6 million, marking a year-over-year increase of 5508.75%. This contributed to the annual value of $13.4 million for FY2025, which is 4593.02% up from last year.
  • InMed Pharmaceuticals' Common Equity amounted to $9.6 million in Q4 2025, which was up 5508.75% from $11.6 million recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Common Equity registered a high of $15.2 million during Q3 2021, and its lowest value of -$9.6 million during Q3 2023.
  • Moreover, its 5-year median value for Common Equity was $11.1 million (2022), whereas its average is $9.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 18701.07% in 2023, then skyrocketed by 18765.26% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Common Equity (Quarter) stood at $14.2 million in 2021, then grew by 1.18% to $14.3 million in 2022, then dropped by 10.9% to $12.8 million in 2023, then tumbled by 51.6% to $6.2 million in 2024, then surged by 55.09% to $9.6 million in 2025.
  • Its Common Equity stands at $9.6 million for Q4 2025, versus $11.6 million for Q3 2025 and $13.4 million for Q2 2025.